Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.
B cell
COVID-19
autoimmune blistering disease
immunosuppression
pemphigus
rituximab
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
02
2021
accepted:
29
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
15
5
2021
Statut:
epublish
Résumé
COVID-19 is characterized by a severe pulmonary disease due to severe acute respiratory syndrome (SARS)-CoV-2 infection. For clinicians involved in the management of patients with chronic autoimmune diseases the risk linked to the conditions itself and to drug-induced immunosuppression during the COVID-19 pandemic is a major topic. Pemphigus is a rare autoimmune blistering disease (AIBD) of the skin and mucous membranes caused by autoantibodies to desmosomal components, desmoglein 1 and 3. Among immunosuppressant therapies, rituximab (RTX) is considered a highly effective treatment with a favorable safety profile, but it induces a prolonged B-cell depletion that can lead to higher susceptibility to infections. For this reason, concerns about its use during the pandemic have been raised. We describe a case of a pemphigus patient in which RTX-induced B cell depletion led to the severe inflammatory phase, whereas corticosteroid treatment allowed a favorable outcome.
Identifiants
pubmed: 33936104
doi: 10.3389/fimmu.2021.665522
pmc: PMC8087171
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunoglobulin G
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
665522Informations de copyright
Copyright © 2021 Sinagra, Vedovelli, Binazzi, Salemme, Moro, Mazzanti, Didona and Di Zenzo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
J Am Acad Dermatol. 2021 Apr;84(4):1098-1100
pubmed: 33359593
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312864
J Eur Acad Dermatol Venereol. 2021 Mar 2;:
pubmed: 33655539
Front Immunol. 2021 Feb 18;12:631226
pubmed: 33679778
J Med Virol. 2020 Oct;92(10):2188-2192
pubmed: 32436996
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
J Exp Med. 2008 Mar 17;205(3):711-23
pubmed: 18332179
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e295-e297
pubmed: 32302437
J Dermatolog Treat. 2020 Jul 9;:1-2
pubmed: 32594787
Dermatol Ther. 2021 Jan;34(1):e14647
pubmed: 33296557
Dermatol Ther. 2020 Nov;33(6):e14265
pubmed: 32882079
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Semin Arthritis Rheum. 2020 Aug;50(4):564-570
pubmed: 32425260
Front Immunol. 2019 Jun 25;10:1418
pubmed: 31293582
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Dermatol Ther. 2020 Nov;33(6):e14398
pubmed: 33040414
Nat Commun. 2021 Mar 5;12(1):1428
pubmed: 33674591
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Am Acad Dermatol. 2021 Apr;84(4):e197-e198
pubmed: 33130180
Drugs. 2018 Oct;78(15):1527-1548
pubmed: 30238396
Lancet. 2017 May 20;389(10083):2031-2040
pubmed: 28342637
J Am Acad Dermatol. 2020 Mar;82(3):575-585.e1
pubmed: 29438767
Ann Rheum Dis. 2021 Feb;80(2):e18
pubmed: 32321723
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5
pubmed: 24599590
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
J Am Acad Dermatol. 2020 Jun;82(6):e235-e236
pubmed: 32283243
J Am Acad Dermatol. 2021 Feb;84(2):563-568
pubmed: 32781181
J Formos Med Assoc. 2005 Feb;104(2):75-81
pubmed: 15765160
Clin Immunol. 2020 Aug;217:108509
pubmed: 32535188
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
Front Immunol. 2020 Dec 21;11:633815
pubmed: 33408723
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632